Sichuan Goldstone Asia Pharmaceutical (300434.SZ) Earnings Analysis
Sichuan Goldstone Asia Pharmaceutical (300434.SZ) has no confirmed upcoming earnings date. Trailing P/E 22.56.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 300434.SZ next report earnings?
No confirmed upcoming earnings date is currently scheduled for 300434.SZ. This page updates as the calendar is published.
300434.SZ earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-06-30 | 0.0072 CNY | n/a | n/a | n/a |
| 2025-05-23 | 0.084 CNY | n/a | n/a | n/a |
| 2025-03-31 | 0.1564 CNY | n/a | n/a | n/a |
| 2024-09-29 | 0.04711 CNY | n/a | n/a | n/a |
300434.SZ valuation and analyst view
| Trailing P/E | 22.56 |
|---|---|
| Trailing EPS | 0.46 CNY |
| Price / book | 1.56 |
| Dividend yield | 0.79% |
| Market cap | 4.17B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Sichuan Goldstone Asia Pharmaceutical (300434.SZ)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 300434.SZ. This page updates as the calendar is published.
Did 300434.SZ beat earnings last quarter?
Consensus estimate data was not available for 300434.SZ's 2025-06-30 report.
What is 300434.SZ's current P/E ratio and EPS?
300434.SZ trades at a trailing P/E of 22.56 on trailing EPS of 0.45999504834440985 CNY.
What do analysts rate 300434.SZ?
300434.SZ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.